Bone Morphogenetic Protein Receptors, Type I
"Bone Morphogenetic Protein Receptors, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of bone morphogenetic protein receptors with high affinity for BONE MORPHOGENETIC PROTEINS. They can interact with and undergo PHOSPHORYLATION by BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II. They signal primarily through RECEPTOR-REGULATED SMAD PROTEINS.
MeSH Number(s)
D08.811.913.696.620.682.700.109.500
D12.776.543.750.750.400.049.500
Concept/Terms
Bone Morphogenetic Protein Receptors, Type I- Bone Morphogenetic Protein Receptors, Type I
- BMPR-I Receptors
- BMPR I Receptors
- Type I Bone Morphogenetic Protein Receptors
- BMP Type I Receptor
- Bone Morphogenetic Protein Receptor Type I
Bone Morphogenetic Protein Receptor, Type IA- Bone Morphogenetic Protein Receptor, Type IA
- Type IA Bone Morphogenetic Protein Receptor
- BMPR-IA Receptor
- BMPR IA Receptor
- Activin Receptor-Like Kinase 3
- Activin Receptor Like Kinase 3
- BMP Type IA Receptor
Bone Morphogenetic Protein Receptor, Type IB- Bone Morphogenetic Protein Receptor, Type IB
- Type IB Bone Morphogenetic Protein Receptor
- BMPR-IB Receptor
- BMPR IB Receptor
- Serine-Threonine Protein Kinase Receptor R6
- Serine Threonine Protein Kinase Receptor R6
- Activin Receptor-Like Kinase 6
- Activin Receptor Like Kinase 6
- BMP Type IB Receptor
Below are MeSH descriptors whose meaning is more general than "Bone Morphogenetic Protein Receptors, Type I".
Below are MeSH descriptors whose meaning is more specific than "Bone Morphogenetic Protein Receptors, Type I".
This graph shows the total number of publications written about "Bone Morphogenetic Protein Receptors, Type I" by people in Harvard Catalyst Profiles by year, and whether "Bone Morphogenetic Protein Receptors, Type I" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 2 | 5 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 3 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 6 | 1 | 7 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Bone Morphogenetic Protein Receptors, Type I" by people in Profiles.
-
BMPR1A promotes ID2-ZEB1 interaction to suppress excessive endothelial to mesenchymal transition. Cardiovasc Res. 2023 05 02; 119(3):813-825.
-
Lethal variants in humans: lessons learned from a large molecular autopsy cohort. Genome Med. 2021 10 13; 13(1):161.
-
mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion. Hum Mol Genet. 2021 06 26; 30(14):1273-1282.
-
BMP Ligand Trap ALK3-Fc Attenuates Osteogenesis and Heterotopic Ossification in Blast-Related Lower Extremity Trauma. Stem Cells Dev. 2021 01 15; 30(2):91-105.
-
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prev Res (Phila). 2021 02; 14(2):215-222.
-
HFE and ALK3 act in the same signaling pathway. Free Radic Biol Med. 2020 11 20; 160:501-505.
-
Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood. 2020 02 06; 135(6):453-456.
-
miR-29a/b1 Inhibits Hair Follicle Stem Cell Lineage Progression by Spatiotemporally Suppressing WNT and BMP Signaling. Cell Rep. 2019 11 19; 29(8):2489-2504.e4.
-
Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis. Cancer Sci. 2019 Nov; 110(11):3486-3496.
-
Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A. Clin Transl Gastroenterol. 2019 07; 10(7):e00054.